Organogenesis (NASDAQ:ORGO) Cut to Sell at Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Organogenesis (NASDAQ:ORGO) from a hold rating to a sell rating in a research note issued to investors on Thursday, reports.

According to Zacks, “Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. “

Several other equities analysts have also commented on the stock. SunTrust Banks reduced their target price on shares of Unisys to $17.00 and set a buy rating on the stock in a report on Thursday, April 11th. Oppenheimer set a $119.00 target price on shares of American Express and gave the company a buy rating in a report on Wednesday, April 17th. Credit Suisse Group reaffirmed a buy rating and set a $19.50 target price on shares of Infineon Technologies in a report on Thursday, May 2nd. CIBC assumed coverage on shares of Organogenesis in a report on Wednesday, April 17th. They set an outperform rating and a $11.00 target price on the stock. Finally, BTIG Research reaffirmed a hold rating on shares of Accelerate Diagnostics in a report on Sunday, May 12th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Organogenesis currently has an average rating of Buy and an average price target of $10.80.

ORGO stock opened at $7.74 on Thursday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.87 and a current ratio of 1.07. Organogenesis has a 52 week low of $6.28 and a 52 week high of $310.90. The firm’s fifty day simple moving average is $7.32.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Friday, May 10th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.05). The company had revenue of $57.12 million for the quarter, compared to the consensus estimate of $55.12 million. Research analysts expect that Organogenesis will post -0.47 earnings per share for the current year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

Recommended Story: Book Value Per Share – BVPS

Get a free copy of the Zacks research report on Organogenesis (ORGO)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with's FREE daily email newsletter.

Leave a Reply